FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION (See section 10, rule 13)
Modified Insecticidal Proteins with Improved Toxicity against Lepidopteran Insects
AJEET SEEDS PVT. LTD. an Indian Company of Gut No. 233, Chitegaon, Paithan Road, Tal. Paithan, Dist. Aurangabad-431105, India
The following specification particularly describes the invention and the manner in which it is to be performed.

FIELD OF INVENTION
The present invention relates to the field of molecular biology. Specifically, the present invention relates to development of modified insecticidal toxins with improved toxicity to control Lepidopteran insect pests.
BACKGROUND OF THE INVENTION
Lepidopteran insects present one of the greatest challenges for insect pest management in Indian agriculture and cause severe damage to important crop plants. Bacillus thuringiensis (Bt) toxins are widely accepted insecticidal proteins and highly efficient / effective in controlling Lepidopteran insects especially on cotton. Bt crops have decreased reliance on conventional insecticides by, suppressing key insect pests, and increased yield adding to farmer’s profit. However, over the period of time, evolution of resistance by insect pests has reduced the benefits of insecticidal proteins from Bt that are used extensively in sprays and transgenic crops. Pink bollworm, Pectinophora gossypiella (Lepidoptera) is a global pest of cotton and currently a major threat for cotton cultivation in India. Some of the recent reports (Tabashnik et al., 2013, Wang et al., 2022) have revealed that field evolved resistance to Bt cotton, Bollguard II, in pink bollworms, could be a major retaliation to Bt cotton technology, the only transgenic technology available against pink bollworm at present.
It is well known that proteolytic activation of Bt toxins, and the subsequent binding to the insect gut epithelium are two important steps involved in the mechanism of Bt Cry protein toxicity. However, mutations in a gene encoding cadherin protein, a receptor of Cry1Ac in pink bollworm gut has led to field-evolved resistance of pink bollworm to Cry1Ac toxins (Fabrick et. al., 2009). Hence, altered or no binding of toxin to the gut receptors is the principal reason behind field evolved resistance in pink bollworm.
To withstand field evolved resistance in pink bollworm, Bt cotton technology needs to be continuously upgraded by introduction of novel or improved Bt Cry toxins with enhanced insecticidal activity. As field evolved Bt resistance in pink bollworm is attributed to altered or no binding of toxin to the gut receptors, increasing binding of Cry toxins to insect gut receptors by various means would be the prudent approach ahead.
This problem can be addressed by modifying the binding target(s), specificity and/or affinity of Bt toxins with the ultimate goal of producing designer toxins that target resistant species and counter the field evolved resistance. The use of synthetic gut binding peptides (GBPs) in the

engineering of Bt toxins is a relatively new approach, which has the potential to restore and/or enhance the toxicity of Bt toxins against pests which have evolved resistance to the Bt toxin (Deist et al., 2014).
Advances in powerful combinatorial technologies such as phage display library (PDL) suggest new approaches for selecting binding peptides (Deist et al., 2014 and Sijun Liu et al., 2010). A phage display peptide library is a mixture of filamentous phage with foreign peptides on their surface and the coding sequences for the peptides in the viral DNA. Surface display is accomplished by fusing the peptide coding sequence to a coat protein encoding gene either in the minor coat protein cpIII or in the major coat protein cpVIII (Scott and Smith 1990). Each phage clone displays a single peptide, but a library as a whole may represent billions of peptides altogether. The vital advantage of surface exposure is that it allows phage display libraries with vast numbers of peptides to be easily surveyed for clones whose displayed peptides bind specifically to any given molecular target. A number of peptides that bind receptor molecules have been identified using phage display libraries (Natalia et. al., 2002).
None of the compositions or methods available in the art have the potential to restore and or enhance the toxicity of Bt toxins against lepidopteran insect pests such as Pectinophora gossypiella (Pink Bollworm), which have evolved resistance to the Bt toxin, by increasing binding of Cry toxins to insect gut receptors. Thus, there is a need for continuous upgradation and development of novel and improved insecticidal proteins that can specifically target the resistant population of Lepidopteran insect pests.
The present invention overcome the problems of the prior art and deals with modification of Cry1Ac protein using pink bollworm gut binding peptides to enhance its gut binding and eventually activity. More particularly, the present invention provides modified Cry1Ac protein(s) with enhanced insecticidal toxicity with great potential for the production of insect resistant transgenic plants resulting in reduced application of costly and environmentally damaging insecticides, for sustained and environmentally sound agricultural productivity.
OBJECTS OF THE INVENTION
An important object of the present invention is to provide modified Cry1Ac toxin(s) with enhanced toxicity towards Lepidopteran insect pests particularly resistant Pink Bollworm.
Another important object of the present invention is to provide modified Cry1Ac protein(s) having improved insecticidal activity/toxicity against Lepidopteran insects

compared to a native Cry1Ac protein and comprising insertion of one or more peptide sequences at one or more amino acid positions of Cry1Ac.
Another important object of the present invention is to provide a method for identification of site(s) in Cry1Ac where insertions of small peptides can be done without affecting the toxicity.
Another object of the present invention is to design a library of novel gut binding peptides (GBPs) capable of binding to resistant pink bollworm gut.
A further object of the present invention is to provide an insecticidal composition(s) comprising said mutant of Cry1Ac protein(s).
Another object of the present invention is to provide a method for production of insect resistant transgenic plants.
Another object of the present invention is to provide a transgenic plant capable of expressing the mutant Cry1Ac protein(s) and resistant to Lepidopteran insects.
Another object of the present invention is to provide a method of inhibiting growth or killing an insect pest, pest population or resistant pest of the order Lepidoptera.
Another object of the present invention is to provide a method to inhibit pests of the order of Lepidoptera specifically Pink Bollworm or resistant population of Pink Bollworm using said Cry1Ac mutant(s).
BRIEF DESCRIPTION OF FIGURES
The accompanying figures illustrate some of the embodiments of the present invention and,
together with the descriptions, serve to explain the invention. These figures have been provided
by way of illustration and not by way of limitation.
Figure 1 provides a schematic representation for identification of pink bollworm (PBW) gut
binding peptides using phage display library.
Figure 2 shows a scheme of overlap extension PCR for the incorporation of peptides and
modification of Cry1Ac protein(s).
Figure 3 shows a schematic representation of Cry1Ac modifications No. 1 to 16. Each selected
peptide was inserted in four insertion sites identified in Cry1Ac coding sequence.
Figure 4 shows schematic representation of Cry1Ac modifications No. 17 to 19. Peptide
AISPSRYFYDET (hereinafter referred to as AIS) was introduced at two, three and four
identified insertion sites in Cry1Ac.
Figure 5 shows schematic representation of Cry1Ac modifications No. 20 to 22. Different
modifications were done by combining AIS @ 282 with APTTWFNSDSIT (hereinafter

referred to as APT) @ 368, SANYNVQAGWTH (hereinafter referred to as SAN) @ 508 and
WAMDGQQHSNNY (hereinafter referred to as WAM) @ 523.
Figure 6 shows method for collection of Cry1Ac resistant Pink Bollworm from infested field
(heavily infested cotton balls and plants) Panel (A): PBW Infested cotton plant, (B): PBW
Infested cotton ball with burrowed PBW inside, (C): PBW on cotton ball, (D): Arrangement of
cotton balls to harvest live PBW.
Figure 7 illustrates four insertion sites for peptides in Cry1Ac labelled as 282, 368, 523 and
582.
Figure 8 shows overlay of native Cry1Ac, Cry1Ac+peptide@282, Cry1Ac+peptide@368,
Cry1Ac+peptide@508, Cry1Ac+peptide@523.
Figure 9 shows results of overlap extension-PCR for peptide insertion. (a) Generation of two
different overlapping fragments (b) Joining of two fragments using overlap extension PCR (c)
Validation of nucleotide insertion using site specific PCR (d) HRM (High Resolution Melt)
profile of native and inserted fragments.
Figure 10 shows Cry1Ac modifications 1, 5, 9 and 13 (as representation). Four different
peptides introduced at the same site (aa282; RG-SAQGIE) and sequence alignments of a region
of insertion (nucleotide followed by amino acid) are shown. Inserted nucleotide and peptide
sequences are shown in grey background.
Figure 11 illustrates confirmation of multiple peptide insertion in Cry1Ac. Lane M: Molecular
weight marker, Lane1: Native Cry1Ac (Molecular weight 3537bp), Lane2: Cry1Ac with first
peptide inserted (Molecular weight 3537+36 = 3573bp), Lane3: Cry1Ac with second peptide
inserted (Molecular weight 3537+36+36 = 3609bp), Lane4: Cry1Ac with third peptide inserted
(Molecular weight 3537+36+36+36 = 3645bp) and Lane5: Cry1Ac with fourth peptide inserted
(Molecular weight 3537+36+36+36+36 = 3681bp).
Figure 12 illustrates the recombinant expression and purification of Native and modified
Cry1Ac. Expression of Native Cry1Ac and one modified toxin (SAN @ 282) is shown as
representative. Lane M: Molecular weight marker, Lanes 1, 2 and 3: Total protein analysis of
bacterial lysate expressing Native Cry1Ac, Lanes 4, 5 and 6: Total protein analysis of bacterial
lysate expressing Modified Cry1Ac (SAN @ 282). Lanes 7 and 8: 2 and 4ug of BSA as standard
Figure 13 shows the results of Western blot analysis of recombinant Cry1Ac (Native and
Modified). Immunoreactivity of native and modified Cry1Ac (SAN @ 282) is shown as
representative. M: Molecular weight marker, Bl: Untransformed bacterial cell lysate, Nt: Cell
lysate of lysate expressing Native Cry1Ac, Lanes (D14, D24, D8 and D13) cell lysates of clones
expressing SAN @ 282.

Figure 14 illustrates the recombinant expression of Cry1Ac incorporated with multiple peptides. LaneM: Molecular weight marker, Lane1: Native Cry1Ac (predicted molecular weight is 133.12 kDa), Lane2: Cry1Ac with first peptide inserted (predicted molecular weight 133.12 + 1.5 = 134.62 kDa), Lane3: Cry1Ac with second peptide inserted (predicted molecular weight 133.12 + 1.5 + 1.5 = 135.12kDa), Lane4: Cry1Ac with third peptide inserted (predicted molecular weight 133.12 + 1.5 + 1.5 + 1.5 = 136.62 kDa) Lane5: Cry1Ac with fourth peptide inserted (predicted molecular weight 133.12 + 1.5 + 1.5 + 1.5 + 1.5 = 138.12kDa).
Figure 15 shows the Mortality of Cry1Ac resistant PBW larvae fed with native and modified Cry1Ac(s).
Figure 16 shows comparison of growth retardation in PBW larvae fed with native and modified Cry1Ac(s). AD: Artificial Diet only, Native (Native Cry1Ac).
SUMMARY OF THE INVENTION
The present invention primarily provides modified Cry1Ac protein(s) having enhanced toxicity towards resistant Pink Bollworm (PBW) insect population. More particularly, the present invention relates to identification of specific insertion sites in Cry1Ac and engineering of Cry1Ac(s) by insertion of gut binding peptides into said sites based on in silico studies and modification approach. Insertion of said specific, tightly binding gut peptides in Cry1Ac at one or more identified sites increases the retention of toxin in the PBW gut, resulting in solubilisation and pore formation leading to sepsis and larval death.
The modified Bt toxin(s) exhibit significant toxicity against resistant pink bollworm and thus can be used for generation of insect resistant transgenic plants. More particularly, development of transgenic cotton expressing modified Cry toxins with higher potency, which over the period of time can delay field evolved insect resistance and this will help to sustain Bt cotton technology for a longer duration.
DETAILED DESCRIPTION OF INVENTION
At the very outset, it may be understood that the ensuing description only illustrates a particular form of this invention. However, such a particular form is only an exemplary embodiment, without intending to imply any limitation on the scope of this invention. Accordingly, the description and examples are to be understood as exemplary embodiments for teaching the invention and not intended to be taken restrictively.

The details of one or more embodiments of the invention are set forth in the accompanying description below including specific details of the best mode contemplated by the inventors for carrying out the invention, by way of example. It will be apparent to one skilled in the art that the present invention may be practiced without limitation to these specific details.
Abbreviations
Bt- Bacillus thuringiensis
E. coli- Escherichia coli
EDTA- Ethylenediaminetetraacetic acid
GBP-Gut binding peptide
OLE-PCR- Overlap Extension PCR
PBS- Phosphate Buffered Saline
PBW- Pink Bollworm
SDS-PAGE- Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Tris-HCl- Tris Hydrochloride
Definitions:
Unless contraindicated or noted otherwise, throughout this specification, the terms “a” and “an” mean one or more, and the term “or” means and/or.
The use of “comprise”, “comprises”, “comprising”, “contain”, “contains”, “containing”, “include”, “includes”, and “including” are not intended to be limiting. It is to be understood that both the foregoing general description and this detailed description are exemplary and explanatory only and are not restrictive. Wherever there is an indefinite article used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Unless otherwise defined, scientific and technical terms used herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

As used herein, biotechnological terms have their conventional meaning as illustrated by the following illustrative definitions:
The term “recombinant” used herein relates to or denotes an organism, cell, or genetic material produced by combining genetic material from more than one origin.
The term “modified” refers to a modified cry protein. The synonyms such as mutant, recombinant, engineered etc. may be used interchangeably and is commonly understood by the person skilled in the art.
The term “insect” refers to insects or pests that feed on Bt cotton plants. Related terms such as pest, pest population or resistant pest are also to be interpreted in a similar manner.
The present invention deals with the modification of Cry1Ac protein using pink bollworm gut binding peptides to enhance its gut binding and eventual insecticidal activity. The inventors of the present invention identified specific site(s) in Cry1Ac coding sequence, where gut binding peptides can be inserted without altering the toxicity of the protein. This was achieved using in silico structural analysis of Cry1Ac protein. Further, the specific and gut binding peptides (GBPs) binding to the resistant Pink Bollworm gut were identified using phage display library. The gut binding peptides frequently appearing in the selected phage population and exhibiting higher phage recovery than other clones were selected. Identified gut binding peptides were then inserted in the specific sites of Cry1Ac identified in the first part, using OLE-PCR. Further to this, the modified toxins with inserted gut binding peptides were recombinantly expressed and partial purification was carried out. Partially purified toxins (both native and modified) were fed to resistant PBW larvae in artificial diets and mortality was observed.
In an important embodiment, the present invention involves identification of specific sites in Cry1Ac protein where modifications/small insertions can be done without altering conformation of protein and toxicity.
In another embodiment, the present invention provides novel gut binding peptides identified using phage display library.
In another important embodiment, the present invention provides modified Cry1Ac protein(s) with enhanced toxicity against field Bt-resistant PBW population.

In an embodiment of the present invention, one or more gut binding peptides of 12 amino acid residues selected from SEQ ID NO: 1 to 82 are inserted at at least one of the specific sites selected from amino acid positions 189, 223, 282, 334, 368, 469, 508, 523, 666 and 834 (Fig. 1) of Cry1Ac without affecting the activity and toxicity of the protein.
In a further embodiment, the present invention provides a modified Cry1Ac peptide having insertion of one or more gut binding peptide at two, three and four different sites in Cry1Ac.
An embodiment of the present invention also relates to inhibition of the Lepidopteran pests, specifically Pectinophora gossypiella (Pink Bollworm).
An embodiment of the present invention also relates to extending and using this method for modification of proteins in Bt technology for other related plants not limited to Bt cotton plant.
In an embodiment, the present invention provides a modified Cry1Ac protein comprising one or more gut binding peptide (GBP) sequences selected from SEQ ID NO: 1 to 82, inserted at at least one of the amino acid positions selected from 189, 223, 282, 334, 368, 469, 508, 523, 666 and 834 of Cry1Ac, wherein said mutant Cry1Ac protein has improved insecticidal activity/toxicity against Lepidopteran insects specifically Bt resistant pink bollworm (PBW) compared to native Cry1Ac protein.
In another embodiment of the present invention, the insect is pest, pest population or resistant pest species of Lepidopteran insects specifically pink bollworm (PBW).
In a further embodiment, the present invention provides a method of identifying one or more stable target site(s) in native Cry1Ac protein for insertion of a gut binding peptide comprising: i. in silico studies comprising structural analysis and insertion of known gut binding peptides to check stability of the protein pre and post insertion; and ii. identification and selection of stable sites based on the stability results.
In another embodiment, the stable target sites are selected from amino acid positions 189, 223, 282, 334, 368, 469, 508, 523, 666 and 834 of Cry1Ac.

In a further embodiment, the present invention provides a method of preparing the modified Cry1Ac protein, comprising:
a) identifying the gut binding peptides (GBPs);
b) in silico identification of one or more stable target site(s) in Cry1Ac protein for insertion of one or more said gut binding peptide(s); and
c) modification of native Cry1Ac gene by insertion of one or more GBPs at atleast one or more identified sites to obtain the modified Cry1Ac protein,
wherein said modified Cry1Ac protein has improved insecticidal activity/toxicity against Lepidopteran insects specifically Bt resistant pink bollworm (PBW) compared to native Cry1Ac protein.
In another embodiment, the method of identifying gut binding peptides comprises:
i. Screening a phage display library using biopanning protocol;
ii. feeding the insect larvae on the phage display library using either artificial diet
or coated cotton balls;
iii. dissecting of larval guts;
iv. elution for bound phages;
v. amplification and enrichment of eluted phages via transfection into host cells
for creating a library of peptides;
vi. analysis of individual clones and sequencing; and
vii. shortlisting gut binding peptides that bind to the gut of the insect, wherein the
gut binding peptides frequently appearing in the selected phage population and exhibiting higher phage recovery than other clones were selected.
In another embodiment, the present invention provides a polynucleotide comprising a nucleic acid molecule encoding the modified Cry1Ac protein(s) of the present invention.
In yet another embodiment, the present invention provides a vector comprising the polynucleotide of the present invention.
In a further embodiment, the present invention provides a host cell transformed using the vector of the present invention, wherein said cell is capable of expressing modified Cry1Ac(s).
In another embodiment, the host cell is a plant cell.

In yet another embodiment, the present invention provides a method of producing an insect-resistant transgenic plant, comprising:
a. stably integrating the polynucleotide into the genome of a host/plant cell; and
b. obtaining a stably transformed plant from plant/ plant cell capable of expressing the modified
Cry1Ac, wherein said stably transformed plants are resistant to Lepidopteran insects.
In a further embodiment, the present invention provides a library of gut binding peptides (GBPs) comprising peptides having 12 amino acid residues and defined by SEQ ID NO: 1 to 82 wherein said peptides are capable of binding to one or more gut receptors of Lepidopteran insects.
In another embodiment, the present invention provides an insecticidal formulation comprising an effective amount of the modified Cry1Ac protein(s).
In another embodiment, the present invention provides a composition comprising the insecticidal formulation along with one or more formulating agents selected from but not limited to the group consisting of adjuvants, surfactants, thickeners, stickers, petroleum oils, crop oil concentrate, stabilizing agents, solvents, hygroscopic agents, deposit builders, antifoam agents, buffering agents and activators.
In a further embodiment, the present invention provides a method of inhibiting the growth of an insect pest, insect pest population, or resistant lepidopteran insect pests, comprising contacting said insect pest(s) with the modified Cry1Ac protein.
In yet another embodiment, the present invention provides a method for improving the yield of a crop using the insecticidal formulation.
EXAMPLES
The following examples particularly describe the manner in which the invention is to be performed. But the embodiments disclosed herein do not limit the scope of the invention in any manner.
Example 1: Identification and Preparation of the modified Cry1Ac Protein

1.1 Identification Gut Binding Peptides (GBPs)
A phage display library containing 12 amino acid residue peptides was screened by using biopanning protocol with resistant pink bollworm larvae (Liu et al., 2010). Larvae were fed on a phage display library using either artificial diet or coated cotton balls. Larval guts were subsequently dissected and eluted for bound phages. Eluted phages were amplified and the enrichment was done by transfecting the host cells to create a library of peptides. The library was screened by either screening of individual clone or by following Next-Gen sequencing. The overall scheme is represented in Figure 1. Screening of the library generated a list of few hundred peptides containing 12 amino acid residues (36 nucleotides). However, only 84 peptides showing higher abundance were considered.
1.2 In silico Identification of sites in Cry1Ac suitable for peptide insertion
To identify the sites in Cry1Ac where gut binding peptides can be inserted, in silico studies were carried out. The approach was to randomly insert peptides sequences in different Cry1Ac sites using molecular docking and study the stability of toxin pre and post insertion. Selected peptides (ligands) were processed for docking studies using LigPrep in Schrodinger. Interaction analysis of selected peptides with Cry1Ac model was performed to get insight into exact site(s) and strengths of binding. All ionization states were significantly populated for the pH range 7.0+/-2.0. Desalting was carried out followed by generation of tautomers. ZRANK docking scores were generated and interface salvation energies (kcal/mol) for peptide integrated Cry1Ac studied.
1.3 Modification of Cry1Ac gene by inserting identified GBPs
Codon optimisation was done for the obtained peptide sequences for bacterial expression and primers were designed for insertion of these gut binding nucleotides in the selected sites in Cry1Ac. From the list of peptides obtained, four peptides viz. AIS, APT, SAN and WAM were selected initially for cloning purpose. Insertion of 36 nucleotides at a specific site in Cry1Ac coding sequence was achieved using OLE-PCR. Amplification was carried out using specific PCR conditions. Overall scheme of OLE PCR is shown in Figure 2.
Each selected peptide was inserted at 4 different insertion sites (viz. 282, 368, 508 and 523) generating 16 different modified toxins (Number 1 to 16). The schematic representation of the modifications obtained is shown in figure 3. The modified toxins were recombinantly

expressed, partially purified and insect feeding bioassays were conducted. From the results obtained, best performing peptide and respective site in Cry1Ac were selected.
Exemplary modified Cry1Ac representative sequences with Single Insertions (Inserted peptides shown in bold)
SEQ ID NO: 83 (Insertion of peptide AISPSRYFYDET at 189 / 190)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIAISPSRYFYDETNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPP RQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFN GSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 84 (Insertion of peptide APTTWFNSDSIT at 223 / 224)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSAPTTWFNSDSITRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPP RQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFN GSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG

EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 85 (Insertion of peptide MPLRYPTQVTLD at 282 / 283)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGMPLRYPTQVTLDSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPP RQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFN GSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 86 (Insertion of peptide SANYNVQAGWTH at 334 / 335)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTSANYNVQAGWTHFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPP RQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFN GSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP

ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 87 (Insertion of peptide DGSMLNRMRGFS at 368 / 369)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRDGSM LNRMRGFSRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPP RQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFN GSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 88 (Insertion of peptide WAMDGQQHSNNY at 479 / 480)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRRPFN IGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPPRQGFSHRLSHVS MFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGWAMDGQQHSNNYNFLFN GSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP

ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 89 (Insertion of peptide EPELDNARVLQI at 508 / 509)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRRPFN IGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPPRQGFSHRLSHVS MFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFNGSVISGPGFTGG DLVRLNSSGNNIEPELDNARVLQIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 90 (Insertion of peptide APTTWFNSDSIT at 523 / 524)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRRPFN IGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPPRQGFSHRLSHVS MFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFNGSVISGPGFTGG DLVRLNSSGNNIQNRGYIEVPIHFPSTAPTTWFNSDSITSTRYRVRVRYASVTPIHLNVNWG NSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPV TATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP

ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 91 (Insertion of peptide APTTWFNSDSIT at 666 / 667)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRRPFN IGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPPRQGFSHRLSHVS MFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFNGSVISGPGFTGG DLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWGNSSIFSNTVPAT ATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPVTATLEAEYNLER AQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRAPTTWFNSDSITELSE KVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYP TYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIG KCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
SEQ ID NO: 92 (Insertion of peptide WAMDGQQHSNNY at 834 / 835)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATINSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRRELTLTVLDIVSLFP NYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMDILNSITIYTDAH RGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRRPFN IGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLDEIPPQNNNVPPRQGFSHRLSHVS MFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVKGNFLFNGSVISGPGFTGG DLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVTPIHLNVNWGNSSIFSNTVPAT ATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPVTATLEAEYNLER AQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSEKVKHAKRLSDER NLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYPTYLYQKIDESKL KAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHL EWNPDLDCSCRDGEKCAHHSHHFSLDIDWAMDGQQHSNNYVGCTDLNEDLGVWVIFKIKTQD GHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQY DQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIK NGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYG EGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVP

ADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTF IVDSVELLLMEE
1.4 Modification of Cry1Ac with multiple insertions of peptides
It was hypothesized that insertion of more copies of the peptides could enhance binding to the gut leading to more toxicity. Insertion of the peptide AIS was carried out at two, three and four different sites in Cry1Ac and modifications (No. 17 to No. 19) were done, as shown in figure 4. Multiple insertions of peptides were also carried out using molecular cloning techniques as discussed earlier. Peptides were added one at a time at the desired site of insertion. Successful insertion of multiple peptides was confirmed by gel shift pattern as well as DNA sequencing. The modified Cry1Acs with double, triple and quadruple insertion of AIS along with previously used single insertion were recombinantly expressed, partially purified and insect feeding bioassays were carried out.
As introduction of same peptide in more than one site did not show any further enhancement in the activity or toxicity, best performing peptide-insertion site combination (from initial 16 modifications) was explored by the inventors. From the feeding bioassays data, best modification with a combination of peptide and its respective site was selected viz. APT at position 368, SAN at position 508 and WAM at position 523. These modifications were combined with the first successful modification with AIS at position 282 to create modifications No. 20 to 22 as illustrated in Figure 5.
Exemplary modified Cry1Ac representative sequences with Multiple Peptide insertions (inserted peptides shown in bold)
SEQ ID NO: 93 (Insertion of peptide APTTWFNSDSIT at 282/283 and 368/369)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIAPTTWFNSDSITNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRAPTTWFNSDSITRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSL DEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSIT QIPAVKGNFLFNGSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYA SVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTA GVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSD EFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENY VTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTG SLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDL

GVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAK ESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFT AFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGY ILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTS RNRGYNEAPSVPADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDK VWIEIGETEGTFIVDSVELLLMEE
SEQ ID NO: 94 (Insertion of peptide APTTWFNSDSIT at 282/283, 368/369 and 508/509)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIAPTTWFNSDSITNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRAPTTWFNSDSITRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSL DEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSIT QIPAVKGNFLFNGSVISGPGFTGGDLVRLNSSGNNIAPTTWFNSDSITQNRGYIEVPIHFPS TSTRYRVRVRYASVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLG DIVGVRNFSGTAGVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHI DQVSNLVTYLSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGIT IQGGDDVFKENYVTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYN AKHETVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLD IDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKL EWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNA AIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEV SQEVRVCPGRGYILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYT VNQEEYGGAYTSRNRGYNEAPSVPADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYV TKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE
SEQ ID NO: 95 (Insertion of same peptide at 282/283, 368/369, 508/509 and 523/524)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIAPTTWFNSDSITNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYRAPTTWFNSDSITRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSL DEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSIT QIPAVKGNFLFNGSVISGPGFTGGDLVRLNSSGNNIAPTTWFNSDSITQNRGYIEVPIHFPS TAPTTWFNSDSITSTRYRVRVRYASVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGY FEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQ LGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQ PERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIED SQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGE KCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKR AEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAY LPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQR SVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEI

YPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVPADYASVYEEKSYTDGRRENPCELNRG YRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE
SEQ ID NO: 96 (Insertion of different peptides at 282/283 and 368/369)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIMPLRYPTQVTLDNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYREPELDNARVLQIRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSL DEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSIT QIPAVKGNFLFNGSVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYA SVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLGDIVGVRNFSGTA GVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTYLSD EFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDVFKENY VTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYNAKHETVNVPGTG SLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDIDVGCTDLNEDL GVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKLEWETNIVYKEAK ESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNAAIFEELEGRIFT AFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGY ILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYTVNQEEYGGAYTS RNRGYNEAPSVPADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYVTKELEYFPETDK VWIEIGETEGTFIVDSVELLLMEE
SEQ ID NO: 97 (Insertion of three different peptides at 282/283, 368/369 and 508/509)
MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIMPLRYPTQVTLDNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYREPELDNARVLQIRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSL DEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSIT QIPAVKGNFLFNGSVISGPGFTGGDLVRLNSSGNNIMADQTMGLHHGMQNRGYIEVPIHFPS TSTRYRVRVRYASVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFEGANAFTSSLG DIVGVRNFSGTAGVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHI DQVSNLVTYLSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGIT IQGGDDVFKENYVTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYSIRYN AKHETVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLD IDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKL EWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGVNA AIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEWEAEV SQEVRVCPGRGYILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEIYPNNTVTCNDYT VNQEEYGGAYTSRNRGYNEAPSVPADYASVYEEKSYTDGRRENPCELNRGYRDYTPLPVGYV TKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE
SEQ ID NO: 98 (Four different peptide insertions at 282/283, 368/369, 508/509 and 523/524)

MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGLVD IIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNP ALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDA ATIMPLRYPTQVTLDNSRYNDLTRLIGNYTDHAVRWYNTGLERVWGPDSRDWIRYNQFRREL TLTVLDIVSLFPNYDSRTYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIEGSIRSPHLMD ILNSITIYTDAHRGEYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR TLSSTLYREPELDNARVLQIRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSL DEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSIT QIPAVKGNFLFNGSVISGPGFTGGDLVRLNSSGNNIMADQTMGLHHGMQNRGYIEVPIHFPS TAPTTWFNSDSITSTRYRVRVRYASVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGY FEGANAFTSSLGDIVGVRNFSGTAGVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQ LGLKTNVTDYHIDQVSNLVTYLSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQ PERGWGGSTGITIQGGDDVFKENYVTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIED SQDLEIYSIRYNAKHETVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGE KCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKR AEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAY LPELSVIPGVNAAIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQR SVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEI YPNNTVTCNDYTVNQEEYGGAYTSRNRGYNEAPSVPADYASVYEEKSYTDGRRENPCELNRG YRDYTPLPVGYVTKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE
The aforementioned exemplary modified Cry1Ac peptide sequences in accordance with the claimed invention are provided for the purpose of representation and should not construed to be limiting.
Example 2: Recombinant expression of native and modified Cry1Ac proteins and partial purification
2.1 Confirmation of protein expression
All modified Cry1Ac clones were confirmed for insertion of peptides and the correct open
reading frames by sequencing. For primary culture, E. coli cells (DH5-α) harbouring
recombinant plasmids (pKK223-3) were inoculated into 6ml LB medium
containing Ampicillin (50µg/ml) and grown overnight at 37˚C with continuous shaking at 180 rpm. Secondary culture of 50ml LB (Ampicillin @50µg/ml) was inoculated with 1% volume of the primary culture and incubated at 37˚C/200rpm. Culture was grown until the OD at 600nm reached to 0.6. Then, the flasks were shifted to 28°C/200rpm for 24 h. After 24 h, culture medium was centrifuged at 5000g for 10 minutes. Pellets were stored at -20˚C until further use.
Out of 50ml culture medium, 1ml was processed to check the protein expression. Remaining culture medium was centrifuged at 8,000g for 10 min. Supernatant was discarded and the pellet

was stored at -20˚C till further use. Pellet of 1ml culture was resuspended in 0.9% NaCl. Centrifugation was carried out again at 8,000g for 10 minutes and the supernatant discarded. Pellet was resuspended in 1mL PBS by vortexing. Sample was then sonicated for 5 sec (1 pulse @ 30% amplitude) to lyse the cells. Cell lysate (80µL) was mixed with 20 µL loading dye and heated at 98˚C for 10 min. Sample was then cooled for 5 min at room temperature and centrifuged at 8,000g for 10 min. Supernatant (40 µL) was loaded onto SDS (12% resolving) gel. Electrophoresis was carried out at constant current of 20mA. After electrophoresis, gel was stained with Coomassie Brilliant Blue R-250 and de-stained with methanol and acetic acid. After confirmation of protein expression in pilot culture, pellet obtained from bulk cultures was processed for purification of inclusion bodies (IB).
2.2 Purification of Cry1Ac Inclusion Bodies
The frozen cell pellets were thawed and 1g pellet was resuspended in 50ml lysis buffer (50mM Tris-HCL, 50mM EDTA, 15% Sucrose, pH8.0) containing Lysozyme (2mg/ml)). The suspension was mixed well by vortexing and incubated at 370C for 1h with constant shaking. The suspension was then homogenized using tissue lyser (@ frequency level-25) for 15 min. This was followed by sonication for 10 min (10 sec pulse @ 30% amplitude). The resultant lysate was centrifuged at 10,000xg for 15 min at 4˚C. The supernatant was discarded, and the pellet vigorously washed with TritonX-100 buffer (2% triton in 0.5m NaCl). The lysate was centrifuged for 10,000xg for 15 min at 4˚C, washed with TritonX-100 thrice.
The resulting pellet was washed with 25mL of 0.5M NaCl solution and mixed well by pipetting. The suspension was vigorously vortexed for 5 min and centrifuged for 15000xg for 15 min at 4˚C. This step (wash with 0.5M NaCl) was repeated 5 times. All washed fractions (supernatants of each wash) were retained for SDS-PAGE analysis.
Distilled water 25mL was added to the pellet and mixed by vigorous vortexing for 5 min and then centrifuged for 15000xg for 15 min at 40C. This step was repeated once. The pellet obtained after the final wash containing purified IBs were solubilised in 5mL of solubilisation buffer (50mM sodium carbonate, pH8.0) by vigorous mixing or by vortexing for 5 min. The mixture was incubated at 37˚C for 2-3 h with constant shaking at 200rpm and then centrifuged at 15000xg for 15 min at room temperature. The supernatant was collected and the solubilized IBs were analysed on SDS-PAGE and stored at -20˚C for future use.
2.3 Collection and artificial rearing of Cry1Ac resistant population of PBW

Pink Bollworm larvae were collected for the purpose of testing and validation from Bt cotton fields from historically known hot spot (Akola in Maharashtra) for PBW attack. The Bt-cotton plants were confirmed by using Cry1Ac lateral flow strips (LFS). Approx. 16,000 mature Bt-cotton balls showing larval burrow signs, pores or feeding larvae were collected and brought back to the insectary (heavily infested plants and balls are shown in figure 6 Panel-A). A special tray was designed, and infected balls were arranged to ensure that the larvae will drop in the tray below (as shown in figure 6 Panel-D).
The larvae were carefully removed from the tray and transferred on Artificial Diet (AD). First generation was maintained on AD containing 0.1 ppm partially purified Cry1Ac protein. The concentration of Cry1Ac was stepwise increased for each of the future generations. Larvae to pupae progression, mating of adults, collection and hatching of eggs was performed as per the standard practice for PBW artificial rearing. As the concentration of Cry1Ac increased, larval growth and molting was affected. Sometimes, larval duration extended more than normal. Pupation, adult emergence was also severely affected (especially at higher concentrations). However, despite of the conditions, the population of PBW increased slowly. Generation of Cry1Ac resistant PBW population, details of toxin concentration, number of larvae per generation, and larval number obtained is shown in Table 1 below.
Table 1

Generation No. of Larvae Artificial Diet (AD) composition Cry1Ac Concentration
P1 (Field collected) ~16000 BGII ball -
P2 ~15000 AD+Cry1Ac 0.1 ppm
P3 ~14000 AD+Cry1Ac 1 ppm
P4 ~13170 AD+Cry1Ac 2 ppm
P5 ~7160 AD + C ry1A c 5 ppm
P6 ~1000 AD+Cry1Ac 10 ppm
The larvae once stabilized on 10ppm of Cry1Ac were constantly maintained on the same concentration for further generations and were used for feeding bioassays as required.
2.4 Efficacy of modified Cry1Ac proteins against resistant PBW larvae

The modified toxins were incorporated in the artificial diet and feeding bioassays carried out against susceptible and resistant PBW larvae. The native Cry1Ac protein was used as a control. The PBW larvae were fed on artificial diet (AD) and AD incorporated with native Cry1Ac protein (5 ppm) or modified Cry1Ac proteins (5 ppm). The larval growth and mortality were monitored every day.
3. Results
3.1 Identification of gut binding peptides (GBPs) in resistant PBW larvae
Using phage display library, a list of several gut binding peptides was obtained. List of all abundant peptides along with the codon optimized nucleotide sequence is listed in Table 2 below. Out of which four peptides (AIS, APT, SAN and WAM) were randomly selected for the insertion and further studies.
Table 2

SEQ ID NO Amino acid sequence Nucleotide sequence of Peptides
1 MPLRYPTQVTLD ATGCCTCTGAGGTATCCGACTCAGGTTACGCTGGAT
2 DGSMLNRMRGFS GATGGTTCTATGCTTAATCGGATGCGTGGTTTTAGT
3 APTTWFNSDSIT GCGCCTACTACGTGGTTTAATAGTGATTCGATTACT
4 FKQDAWEAVDIR TTTAAGCAGGATGCGTGGGAGGCTGTTGATATTCGT
5 EPELDNARVLQI GAGCCGGAGTTGGATAATGCTCGGGTGCTTCAGATT
6 MADQTMGLHHGM ATGGCGGATCAGACGATGGGGCTGCATCATGGTATG
7 AFSTTHRYSELI GCTTTTTCGACGACTCATAGGTATAGTGAGCTGATT
8 STMTESIRQRWD TCTACTATGACTGAGAGTATTCGTCAGCGGTGGGAT
9 AISPSRYFYDET GCGATTTCGCCGTCGCGTTATTTTTATGATGAGACG
10 FKQDAWEAVDIR TTTAAGCAGGATGCGTGGGAGGCTGTTGATATTCGT
11 EPELDNARVLQI GAGCCGGAGTTGGATAATGCTCGGGTGCTTCAGATT
12 YALGRPSLQGPN TATGCTCTTGGTAGGCCGTCTCTTCAGGGGCCGAAT
13 DGSMLNRMRGFS GATGGTTCTATGCTTAATCGGATGCGTGGTTTTAGT
14 DNHTTDLWNFSH GATAATCATACGACGGATCTTTGGAATTTTTCTCAT
15 QQMHEWYFQSLP CAGCAGATGCATGAGTGGTATTTTCAGAGTTTGCCG
16 MPLRYPTQVTLD ATGCCTCTGAGGTATCCGACTCAGGTTACGCTGGAT

17 STTAVSPVNSAK TCTACTACTGCTGTGTCTCCTGTGAATTCTGCTAAG
18 APTTWFNSDSIT GCGCCTACTACGTGGTTTAATAGTGATTCGATTACT
19 QELHYGLSSKRF CAGGAGCTTCATTATGGGCTTTCTAGTAAGCGTTTT
20 SVSVNNATLYFY TCGGTTAGTGTTAATAATGCGACTTTGTATTTTTAT
21 HGDGIKMMRQRM CATGGTGATGGTATTAAGATGATGCGTCAGAGGATG
22 SMPRLWDNTSNT TCTATGCCGCGGCTTTGGGATAATACGTCTAATACG
23 SLELKRSDVQHA AGTCTTGAGCTTAAGAGGAGTGATGTGCAGCATGCG
24 AMTDPWLSDSRS GCGATGACGGATCCTTGGTTGTCGGATTCTAGGTCG
25 YSTVYPVGQFPQ TATTCTACTGTTTATCCTGTTGGTCAGTTTCCTCAG
26 TTLWLDRDEALK ACTACTTTGTGGCTTGATAGGGATGAGGCTTTGAAG
27 FSTDYAWTAEAT TTTTCTACTGATTATGCGTGGACGGCTGAGGCGACG
28 SANYNVQAGWTH TCGGCGAATTATAATGTGCAGGCTGGGTGGACGCAT
29 SPKSMTTGTVVV TCTCCTAAGTCGATGACGACTGGGACGGTGGTTGTG
30 MADQTMGLHHGM ATGGCGGATCAGACGATGGGGCTGCATCATGGTATG
31 ASSPRHSFAMGS GCTAGTAGTCCTCGGCATAGTTTTGCTATGGGGTCT
32 ISNAVNEIRTLR ATTAGTAATGCGGTTAATGAGATTCGTACGCTTAGG
33 AHNEDKWVTHRS GCTCATAATGAGGATAAGTGGGTTACTCATAGGTCT
34 GTVSYMVKMDNN GGTACTGTGTCGTATATGGTGAAGATGGATAATAAT
35 FNSDSRSTHQED TTTAATTCTGATTCGCGTAGTACTCATCAGGAGGAT
36 NQCKECFIRAGD AATCAGTGTAAGGAGTGTTTTATTCGGGCGGGGGAT
37 FGLEPRANLHFT TTTGGTCTGGAGCCGAGGGCGAATCTGCATTTTACT
38 KIYTITSSHDSY AAGATTTATACGATTACGTCGAGTCATGATTCTTAT
39 SNSHPNWVELRP TCGAATTCTCATCCGAATTGGGTTGAGCTTCGGCCT
40 WDSLSYPWRITL TGGGATTCTCTTTCTTATCCTTGGAGGATTACTCTG
41 IATQKIHVDTKQ ATTGCTACTCAGAAGATTCATGTTGATACTAAGCAG
42 WDTSWNFPDQPD TGGGATACTAGTTGGAATTTTCCTGATCAGCCGGAT
43 GGWQSLWDKPEH GGGGGTTGGCAGTCGCTTTGGGATAAGCCGGAGCAT
44 VAGNKSVSTSHI GTGGCTGGTAATAAGTCGGTTTCTACTTCGCATATT
45 GHAHSLTQNPLF GGGCATGCTCATTCGCTGACGCAGAATCCGTTGTTT
46 EQWYYSPPIYAN GAGCAGTGGTATTATTCTCCTCCTATTTATGCTAAT
47 VDKQHHTAVFPH GTTGATAAGCAGCATCATACTGCGGTTTTTCCTCAT
48 VDIKSHFSHTGK GTGGATATTAAGTCTCATTTTTCGCATACTGGGAAG
49 VVDPNHSVWILS GTTGTTGATCCTAATCATAGTGTTTGGATTCTGAGT

50 FSDAGNLPANAM TTTTCTGATGCTGGTAATTTGCCGGCTAATGCTATG
51 HTKLLTYTKSTG CATACGAAGTTGCTGACGTATACGAAGAGTACTGGT
52 YPTTANRMYTSY TATCCTACTACGGCTAATAGGATGTATACTAGTTAT
53 IGKSSNAPSLRA ATTGGGAAGTCTTCGAATGCTCCGAGTTTGCGTGCT
54 DGQVSDHSYVQW GATGGTCAGGTTAGTGATCATAGTTATGTTCAGTGG
55 DKYEFFSPTQHY GATAAGTATGAGTTTTTTTCGCCTACGCAGCATTAT
56 SLQTLRLGHNTS TCTCTGCAGACTCTGAGGCTTGGGCATAATACTAGT
57 WDMWPSMDWKAE TGGGATATGTGGCCGTCTATGGATTGGAAGGCGGAG
58 AEPVRDRTQTPK GCGGAGCCTGTGCGTGATAGGACTCAGACTCCTAAG
59 EMHKRVLTWNMI GAGATGCATAAGCGGGTTCTGACTTGGAATATGATT
60 SVFSSFAIFMDH TCTGTGTTTTCTAGTTTTGCGATTTTTATGGATCAT
61 QIEPGDLEHYPT CAGATTGAGCCTGGGGATTTGGAGCATTATCCTACG
62 VNRSGIETGAVK GTTAATCGGAGTGGTATTGAGACGGGGGCTGTGAAG
63 KVSMQADFWSVM AAGGTTTCTATGCAGGCTGATTTTTGGAGTGTGATG
64 EMHGMPLPMLLA GAGATGCATGGTATGCCTTTGCCTATGCTTCTTGCT
65 NGAYSLAIRYTS AATGGTGCTTATAGTCTGGCGATTAGGTATACTTCT
66 WAMDGQQHSNNY TGGGCTATGGATGGGCAGCAGCATAGTAATAATTAT
67 GATSVGSVAMQN GGGGCTACGAGTGTTGGGAGTGTTGCGATGCAGAAT
68 AYAAMGGPSQEK GCTTATGCTGCGATGGGTGGGCCGTCTCAGGAGAAG
69 SLKPPMHYANMY TCTCTTAAGCCGCCGATGCATTATGCGAATATGTAT
70 SYDGTMLKQVRL AGTTATGATGGTACTATGCTGAAGCAGGTTCGGCTT
71 LDMYSYIETYNS CTTGATATGTATAGTTATATTGAGACGTATAATAGT
72 THDMGKMDRTTT ACGCATGATATGGGTAAGATGGATCGGACGACTACT
73 ADNVLRRALENI GCGGATAATGTGCTTCGGCGTGCGCTTGAGAATATT
74 SVPAKKAIDWYS TCGGTTCCGGCTAAGAAGGCGATTGATTGGTATTCG
75 VHASGFRDSQRW GTGCATGCGAGTGGTTTTCGGGATTCGCAGAGGTGG
76 THKLSDWEDIGV ACACATAAGCTGTCTGATTGGGAGGATATTGGTGTG
77 GSHNTYIESTIP GGGTCTCATAATACTTATATTGAGAGTACTATTCCG
78 GFPVPTKEGNRH GGGTTTCCTGTGCCGACTAAGGAGGGTAATAGGCAT
79 IPLENQHKIYST ATTCCTCTTGAGAATCAGCATAAGATTTATTCGACG
80 SKISNMQGLHRT TCGAAGATTTCTAATATGCAGGGTTTGCATCGGACT
81 KDGMPWNIGYSR AAGGATGGGATGCCGTGGAATATTGGTTATTCTCGT
82 QSRTYSGAELLT CAGTCTAGGACTTATAGTGGGGCTGAGTTGTTGACG

3.2 Identification of peptide insertion sites in Cry1Ac
The coding sequence of Cry1Ac contains 1179 amino acid residues. Based on the data obtained in molecular docking studies, 10 potential amino acid residues (189, 223, 282, 334, 368, 469, 508, 523, 666, 834) were identified where insertion of peptides can be done. Table 3 below lists down the residues identified for peptide incorporation based on ZRANK scores wherein residues with ZRANK value < -67.00 were selected (for Native Cry1Ac ZRANK Score was -104.00).
Table 3

S.N.
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Amino acid location Details regarding modifications

Cry1Ac_189 Wild type Cry1Ac (peptide insertion between aa residue 189 and 190)

Cry1Ac_223 Wild type Cry1Ac (peptide insertion between aa residue 223 and 224)

Cry1Ac_282 Wild type Cry1Ac (peptide insertion between aa residue 282 and 283)

Cry1Ac_334 Wild type Cry1Ac (peptide insertion between aa residue 334 and 335)

Cry1Ac_368 Wild type Cry1Ac (peptide insertion between aa residue 368 and 369)

Cry1Ac_479 Wild type Cry1Ac (peptide insertion between aa residue 479 and 480)

Cry1Ac_508 Wild type Cry1Ac (peptide insertion between aa residue 508 and 509)

Cry1Ac_523 Wild type Cry1Ac (peptide insertion between aa residue 523 and 524)

Cry1Ac_666 Wild type Cry1Ac (peptide insertion between aa residue 666 and 667)

Cry1Ac_834 Wild type Cry1Ac (peptide insertion between aa residue 834 and 835)
Among the identified sites, four sites viz. 282, 368, 523 and 582 showed most stable protein conformation after insertion of peptide in in-silico studies. Some representative insertion sites (amino acid residue) with inserted peptide(s) viz. 282, 368, 523 and 582 were used during in silico studies are shown in Figure 7 and the resulting sequence post-insertion of peptides as shown in Table 4.
Table 4

S.N.
1 2 3 Peptide (in bold) inserted region Insertion Site

DGSFRGAISPSRYFYDETSAQGI 282

NSSGNNIAPTTWFNSDSITQNRGYI 368

SSTLYRSANYNVQAGWTHRPFNIGI 523

4 PIHFPSTWAMDGQQHSNNYSTRYRVRV 582
The four selected peptides were inserted at the sites identified in Cry1Ac either one at a time and or multiple and several toxin models were constructed. These models were further docked with wild type and mutant cadherin models and checked for energy.
Overlaying of the predicted structures suggested that the core Cry1Ac structure is not affected by the incorporation of peptide(s) in the loops. Figure 8 shows overlay of modified toxins with insertion of peptide at different positions.
From these studies, it was concluded that potential sites exist in the coding sequence of Cry1Ac wherein gut binding peptides of 12 amino acid residues (36 nucleotides) may be introduced without altering the structure and conformation of the toxin.
3.3 Modifications of Cry1Ac by insertion of single peptide
Various different modifications were achieved by insertion of GBPs at specific sites in Cry1Ac using overlap extension PCR method (Bryksin and Matsumara, 2018). The steps involved and results obtained in PCR, agarose gel electrophoresis, high resolution melt analysis are shown in figure 9. That is by insertion of typical peptide (SANYNVQAGWTH) as following in figure 9:
• Representative (a) shows generation of two different overlapping fragments
• Representative (b) shows joining of two fragments using overlap extension PCR
• Representative (c) shows validation of mutation using mutation specific PCR
• Representative (d) shows HRM profile of mutated fragment.
The successful insertions of peptides in the Cry1Ac were confirmed by sequencing the amplified PCR products. The DNA sequences of modified Cry1Ac toxins showed insertion of 36 nucleotides at the designated insertion site. As a representation, sequence alignments of native and modified toxin for the region of insertion for modifications (AIS @ 282, APT @ 282, SAN @ 282 and WAM @ 523) are shown in figure 10.
3.4 Modifications of Cry1Ac by insertion of multiple peptides

The modified Cry1Ac(s) with multiple peptide insertions (No.17 to No.22) were also generated using OLE PCR technique. The successful insertions were confirmed initially by agarose gel electrophoresis or by gel shift assays (figure 11). The restriction digestion and agarose gel electrophoresis analysis showed expected increment in the molecular weight of DNA.
3.5 Recombinant expression of native and modified Cry1Ac proteins and partial
purification
All Cry1Ac(s) modified by incorporation of peptide were cloned in vector pKK223-3 and expressed in E. coli. Partially purified native and modified Cry1Ac proteins were analysed by SDS-PAGE followed by Coomassie staining. The results are shown in Figure 12. Predicted molecular weight of Cry1Ac is approx. 133.12 kDa. For native Cry1Ac a band of predicted molecular weight was visible. Results for one modified recombinant Cry1Ac with single peptide insertion are shown here. The predicted molecular weight of modified (peptide inserted) Cry1Ac is approx. 134.66 kDa (addition of peptide increases the molecular weight by approximately 1.5 kDa). This can also be visually confirmed by the shift in mobility of the modified Cry1Ac. The partially purified proteins from IBs were visually quantified using known concentrations of BSA as standards and used for insect feeding bioassays.
The total proteins from bacterial lysate were separated by SDS-PAGE on 12% acrylamide gels; sample preparation, running of gels, staining and transfer to nitrocellulose membranes were performed as described earlier (Fitches et al., 2004). Primary (anti Cry1Ac) antibodies used in Western blotting were diluted to 1:5000 for incubation with blots. The detection of immunoreactive bands was done using chemiluminescent detection kit. The western blot results showed immunoreactive bands at the predicted molecular weight for native (133.12 kDa) and modified Cry1Ac (134.65 kDa).
3.6 Recombinant expression of Cry1Ac with multiple peptide insertions
The Cry1Ac(s) modified with multiple peptide insertions (No. 17 to No. 22) showed successful recombinant expression as well as expected migration shift in the SDS-PAGE analysis (Figure 14).
3.7 Efficacy of modified Cry1Ac proteins against Cry1Ac resistant PBW larvae

The susceptible larvae feeding on native and modified Cry1Ac proteins showed 100% mortality. The results of insect feeding bioassays are shown in Figure 15.
All modified toxins (No.1 to No. 7) showed increased toxicity to resistant PBW than the native Cry1Ac. By day 10 of the bioassay, larvae fed on modified Cry1Ac Mod. No. 5 showed about 50% mortality, whereas 13% larval mortality was recorded on native Cry1Ac. The results showed that peptide insertion did not affect protein toxicity rather it significantly increased protein toxicity against Cry1Ac resistant PBW larvae.
Moreover, survived larvae showed significant growth retardation as shown in Figure 16. Larvae were carefully removed from the diet cubes on 13th day of the assay and growth data was recorded.
The Cry1Ac(s) inserted with multiple peptides showed similar levels of toxicity as single insertion Cry1Ac(s) against resistant PBW. The combinations of different gut binding peptides and their insertion at different sites in Cry1Ac may be used further to enhance the toxicity of Cry1Ac. Thus, the present invention has tremendous potential to address the problem of PBW resistance to native Cry1Ac. The modified toxins when expressed in cotton plants could substantially tackle the resistant population of multiple geographies.
ADVANTAGES
1. A unique approach for mitigating/addressing the problem of Bt resistant lepidopteran pests specifically pink bollworm.
2. The invention can be applied to all cotton cultivating geographies facing the above problem.
3. The invention has a high potency to delay field evolved insect resistance and to sustain the Bt cotton technology for a longer duration.
4. The invention has an improved toxicity against pests especially resistant pink bollworm.

We Claim:
1. A modified Cry1Ac protein comprising one or more gut binding peptide (GBP) sequences selected from SEQ ID NO: 1 to 82, inserted at at least one of the amino acid positions selected from 189, 223, 282, 334, 368, 469, 508, 523, 666 and 834 of Cry1Ac, wherein said mutant Cry1Ac protein has improved insecticidal activity/toxicity against Lepidopteran insects specifically Bt resistant pink bollworm (PBW) compared to native Cry1Ac protein.
2. The modified Cry1Ac protein as claimed in claim 1, wherein the insect is pest, pest population or resistant pest species of Lepidopteran insects specifically pink bollworm (PBW).
3. A method of identifying one or more stable target site(s) in native Cry1Ac protein for insertion of a gut binding peptide as defined in claim 1 comprising:
i. in silico studies comprising structural analysis and insertion of known gut
binding peptides to check stability of the protein pre and post insertion; and
ii. identification and selection of stable sites based on the stability results.
4. The method as claimed in claim 3, wherein said stable target sites are selected from
amino acid positions 189, 223, 282, 334, 368, 469, 508, 523, 666 and 834 of Cry1Ac.
5. A method of preparing the modified Cry1Ac protein as claimed in claim 1, comprising:
a. identifying the gut binding peptides (GBPs) as defined in claim 1;
b. in silico identification of one or more stable target site(s) in Cry1Ac protein for
insertion of one or more said gut binding peptide(s); and
c. modification of native Cry1Ac gene by insertion of one or more GBPs at atleast
one or more identified sites to obtain the modified Cry1Ac protein,
wherein said modified Cry1Ac protein has improved insecticidal activity/toxicity against Lepidopteran insects specifically Bt resistant pink bollworm (PBW) compared to native Cry1Ac protein.
6. The method as claimed in claim 5, comprising:
i. screening a phage display library using biopanning protocol;
ii. feeding the insect larvae on the phage display library using either artificial diet
or coated cotton balls;
iii. dissecting of larval guts;
iv. elution for bound phages;
v. amplification and enrichment of eluted phages via transfection into host cells
for creating a library of peptides;

vi. analysis of individual clones and sequencing; and
vii. shortlisting gut binding peptides that bind to the gut of the insect, wherein the
gut binding peptides frequently appearing in the selected phage population and exhibiting higher phage recovery than other clones were selected.
7. A polynucleotide comprising a nucleic acid molecule encoding the modified Cry1Ac protein(s) as claimed in claim 1.
8. A vector comprising the polynucleotide as claimed in claim 7.
9. A host cell transformed using the vector as claimed in claim 8, wherein said cell is capable of expressing modified Cry1Ac(s) claimed in claim 1.
10. The host cell as claimed in claim 9, wherein said host cell is a plant cell. 11. A method of producing an insect-resistant transgenic plant, comprising:
stably integrating the polynucleotide as claimed in claim 7 into the genome of a
host/plant cell; and
b. obtaining a stably transformed plant from plant/ plant cell capable of expressing the
modified Cry1Ac, wherein said stably transformed plants are resistant to Lepidopteran
insects.
14. A library of gut binding peptides (GBPs) comprising peptides having 12 amino acid residues and defined by SEQ ID NO: 1 to 82 wherein said peptides are capable of binding to one or more gut receptors of Lepidopteran insects.
15. An insecticidal formulation comprising an effective amount of the modified Cry1Ac proteins as claimed in claim 1.
16. A composition comprising the insecticidal formulation as claimed in claim 15 along with one or more formulating agents selected from but not limited to the group consisting of adjuvants, surfactants, thickeners, stickers, petroleum oils, crop oil concentrate, stabilizing agents, solvents, hygroscopic agents, deposit builders, antifoam agents, buffering agents and activators.

16. A method of inhibiting the growth of an insect pest, insect pest population, or resistant lepidopteran insect pests, comprising contacting said insect pest(s) with the modified Cry1Ac protein as claimed in claim 1.
17. A method for improving the yield of a crop using the insecticidal formulation as claimed in claim 15 or composition as claimed in claim 16.